세계의 라임병 치료 시장(2024-2031년)

Lyme Disease Treatment Market Size, Share & Trends Analysis Report by Administration Route (Oral, Injectable, and Topical), by Treatment (Medication, and Tick Removal), and by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online) Forecast Period (2024-2031)

Lyme disease treatment market is anticipated to grow at a CAGR of 8.4% during the forecast period (2024-2031). Climate change, expanding tick habitats, and increased outdoor recreational activities spread the Lyme disease. The increasing incidence of Lyme disease, advancements in treatment technologies, and favorable medical insurance policies are major factors driving the global Lyme disease treatment market. The ongoing clinical trials to develop an effective drug for Lyme disease treatment offer a huge opportunity for market development.

Market Dynamics

Increasing Incidence and Prevalence of Lyme cases

The globe is experiencing a significant increase in Lyme-related cases, largely owing to climate change, which is facilitating the spread of species populations into new areas. According to the US Department of Health & Human Services, in 2023, there is an estimated annual diagnosis and treatment of approximately 476,000 cases of Lyme disease in the US. The prevalence of this bacterial infection is expected to increase due to the impact of climate change on tick habitats. Diagnosis of Lyme disease can be challenging due to the similarity of symptoms with other illnesses such as COVID and ME/CFS, requiring clinicians to rely on a combination of laboratory tests and patient history.

Growing Awareness and Diagnosis

The growing population and healthcare clinical awareness of Lyme disease have resulted in accurate diagnoses and a rise in the need for effective therapies such as vaccinations. For instance, in April 2023, Rutgers University launched a Lyme Disease Vaccine Study, aiming to determine the efficacy of a vaccine for children aged 5-17. The study, commissioned by Pfizer and Valneva, aims to evaluate the safety and efficacy of a Lyme disease vaccine. The disease, caused by Borrelia burgdorferi, affects 476,000 Americans.

Further, in May 2023, State Health and Environmental Officials urged prevention to prevent tick bites, and RIDOH launched a new data dashboard for tick-borne diseases. The Rhode Island Department of Health and DEM are urging people to take precautions to prevent tick bites owing to warmer weather and high-incidence Lyme disease, predicting a bad year for tick bites.

Market Segmentation

• Based on the administration route, the market is segmented into oral, injectable, and topical.
• Based on treatment, the market is segmented into medication and tick removal.
• Based on the distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, and online.

Oral Sub-segment to Hold a Considerable Market Share

The easy intake of oral medication and the high efficiency of treatment a major factor driving the growth of this market segment. Therefore, key players are highly focused on the development of oral medications. For instance, in May 2023, US Biologic received USDA Conditional Licensure for its oral Lyme vaccine, which targets the black-legged tick, the leading vector-borne disease in the US. The vaccine, "Borrelia Burgdorferi Bacterin," is spray-coated onto mice's pellets.

Regional Outlook

The Lyme disease treatment market is further segmented based on geography including North America (the US, and Canada), Europe (UK, Italy, Spain, Germany, France, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia-Pacific), and the Rest of the World (the Middle East & Africa, and Latin America).

Growing Healthcare Industry in the Asia-Pacific Region

India's rapidly growing healthcare industry is enhancing the diagnosis, treatment, and management of Lyme disease, with increased investment in facilities and services enhancing the country's capability to address new health concerns. According to statistical data, the healthcare industry in India has experienced a significant growth rate of approximately 22.0% since 2016. Projections suggest that by 2022, the industry will have reached a value of $372.0 billion, making it one of the largest sectors in the Indian economy in terms of revenue and employment.

North America Holds Major Market Share

The increasing prevalence of Lyme disease across the region is the key factor driving demand for the regional Lyme disease treatment market. According to the US News & World Report, L.P. in 2022, the number of reported Lyme disease cases in the US increased by nearly 70.0%. Health officials attribute this rise to changes in reporting requirements rather than a significant increase in new infections. The Centers for Disease Control and Prevention released a report stating that the number of reported cases exceeded 62,000 in 2022, compared to an average of about 37,000 cases per year from 2017 to 2019. It is important to note that these statistics do not capture the full extent of Lyme disease, as only a fraction of the estimated 476,000 annual cases are officially reported.

Market Players Outlook

The major companies serving the Lyme disease treatment market include AbbVie Inc., Bayer AG, F. Hoffmann-La Roche Ltd., Merck & Co., Inc., and Pfizer Inc. among others. The market players are increasingly focusing on business expansion and product development by applying strategies such as collaborations, mergers and acquisitions to stay competitive in the market.

Table of Contents

1. Report Summary

• Current Industry Analysis and Growth Potential Outlook
• 1.1. Research Methods and Tools
• 1.2. Market Breakdown
  • 1.2.1. By Segments
  • 1.2.2. By Region

2. Market Overview and Insights

• 2.1. Scope of the Report
• 2.2. Analyst Insight & Current Market Trends
  • 2.2.1. Key Market Trends
  • 2.2.2. Recommendations
  • 2.2.3. Conclusion

3. Competitive Landscape

• 3.1. Key Company Analysis
• 3.2. AbbVie Inc.
  • 3.2.1. Overview
  • 3.2.2. Financial Analysis
  • 3.2.3. SWOT Analysis
  • 3.2.4. Recent Developments
• 3.3. Bayer AG
  • 3.3.1. Overview
  • 3.3.2. Financial Analysis
  • 3.3.3. SWOT Analysis
  • 3.3.4. Recent Developments
• 3.4. F. Hoffmann-La Roche Ltd.
  • 3.4.1. Overview
  • 3.4.2. Financial Analysis
  • 3.4.3. SWOT Analysis
  • 3.4.4. Recent Developments
• 3.5. Key Strategy Analysis

4. Market Segmentation

• 4.1. Global Lyme Disease Treatment Market by Administration Route
  • 4.1.1. Oral
  • 4.1.2. Injectable
  • 4.1.3. Topical
• 4.2. Global Lyme Disease Treatment Market by Treatment Type
  • 4.2.1. Medication
  • 4.2.2. Tick Removal
• 4.3. Global Lyme Disease Treatment Market by Distribution Channel
  • 4.3.1. Hospital Pharmacies
  • 4.3.2. Retail Pharmacies
  • 4.3.3. Online

5. Regional Analysis

• 5.1. North America
  • 5.1.1. United States
  • 5.1.2. Canada
• 5.2. Europe
  • 5.2.1. UK
  • 5.2.2. Germany
  • 5.2.3. Italy
  • 5.2.4. Spain
  • 5.2.5. France
  • 5.2.6. Rest of Europe
• 5.3. Asia-Pacific
  • 5.3.1. China
  • 5.3.2. India
  • 5.3.3. Japan
  • 5.3.4. South Korea
  • 5.3.5. Rest of Asia-Pacific
• 5.4. Rest of the World
  • 5.4.1. Latin America
  • 5.4.2. Middle East and Africa

6. Company Profiles

• 6.1. Almirall, S.A.
• 6.2. Cipla Ltd.
• 6.3. Eli Lilly and Co.
• 6.4. Gilead Sciences, Inc.
• 6.5. GlaxoSmithKline plc
• 6.6. Hikma Pharmaceuticals PLC
• 6.7. Lupin Pharmaceutical, Inc.
• 6.8. Mayne Pharma Group Ltd.
• 6.9. Merck & Co., Inc.
• 6.10. Novartis AG
• 6.11. Orion Corp.
• 6.12. Perrigo Company plc
• 6.13. Pfizer Inc.
• 6.14. SANOFI S.A.
• 6.15. Sun Pharmaceutical Industries Ltd.
• 6.16. Teva Pharmaceutical Industries Ltd.
• 6.17. Bio-Rad Laboratories, Inc.